Ischemia-reperfusion injury in sickle cell anemia: Relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain

Hematology/Oncology Clinics of North America

Volumn 28, Issue 2, 2014, Pages 181-198

  Hebbel, Robert P ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Endothelial dysfunction; Inflammation; Ischemia reperfusion; Sickle

Indexed keywords

ACUTE CHEST SYNDROME; BIOMEDICINE; ENVIRONMENTAL STRESS; EPIGENETICS; GENETIC POLYMORPHISM; HEMOLYTIC ANEMIA; HUMAN; INFLAMMATORY PAIN; ISCHEMIC PRECONDITIONING; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SICKLE CELL ANEMIA; VASCULAR DISEASE; ANIMAL; BIOLOGICAL MODEL; INFLAMMATION; PAIN; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ACUTE CHEST SYNDROME; ANEMIA, SICKLE CELL; ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; PAIN; REPERFUSION INJURY; VASCULAR DISEASES;

EID: 84896849171     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.11.005     Document Type: Review

References (90)

1. Carden D.L., Granger D.N. Pathophysiology of ischaemia-reperfusion injury. JPathol 2000, 190:255-266.
2. Kalogeris T., Baines C.P., Krenz M., et al. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 2012, 298:229-317.
3. McCord J.M. Oxygen-derived free radicals in postischemic tissue injury. NEngl J Med 1985, 312:159-163.
4. Kvietys P.R., Granger D.N. Role of reactive oxygen and nitrogen species in the vascular responses to inflammation. Free Radic Biol Med 2012, 52:556-592.
5. Ley K., Laudanna C., Cybulsky M.I., et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007, 7:678-689.
6. Sun Z., Andersson R. NF-kappaB activation and inhibition: a review. Shock 2002, 18:99-106.
7. Arumugam T.V., Okun E., Tang S.C., et al. Toll-like receptors in ischemia-reperfusion injury. Shock 2009, 32:4-16.
8. Strbian D., Kovanen P.T., Karjalainen-Lindsberg M.L., et al. An emerging role of mast cells in cerebral ischemia and hemorrhage. Ann Med 2009, 41:438-450.
9. Liao Y.F., Zhu W., Li D.P., et al. Heme oxygenase-1 and gut ischemia/reperfusion injury: a short review. World J Gastroenterol 2013, 19:3555-3561.
10. Bone R.C. Sepsis and coagulation. An important link. Chest 1992, 101:594-596.
11. Projahn D., Koenen R.R. Platelets: key players in vascular inflammation. JLeukoc Biol 2012, 92:1167-1175.
12. Frey R.S., Ushio-Fukai M., Malik A.B. NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology. Antioxid Redox Signal 2009, 11:791-810.
13. Alkaitis M.S., Crabtree M.J. Recoupling the cardiac nitric oxide synthases: tetrahydrobiopterin synthesis and recycling. Curr Heart Fail Rep 2012, 9:200-210.
14. Lowenstein C.J., Morrell C.N., Yamakuchi M. Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med 2005, 15:302-308.
15. Lipowsky H.H., Gao L., Lescanic A. Shedding of the endothelial glycocalyx in arterioles, capillaries, and venules and its effect on capillary hemodynamics during inflammation. Am J Physiol Heart Circ Physiol 2011, 301:H2235-H2245.
16. Gil J. Organization of microcirculation in the lung. Annu Rev Physiol 1980, 42:177-186.
17. Burns A.R., Smith C.W., Walker D.C. Unique structural features that influence neutrophil emigration into the lung. Physiol Rev 2003, 83:309-336.
18. Bailey T.G., Birk G.K., Cable N.T., et al. Remote ischemic preconditioning prevents reduction in brachial artery flow-mediated dilation after strenuous exercise. Am J Physiol Heart Circ Physiol 2012, 303:H533-H538.
19. Thompson J.W., Dave K.R., Young J.I., et al. Ischemic preconditioning alters the epigenetic profile of the brain from ischemic intolerance to ischemic tolerance. Neurotherapeutics 2013, 10(4):789-797.
20. Zhao Z.Q. Postconditioning in reperfusion injury: a status report (invited review). Cardiovasc Drugs Ther 2010, 24:265-279.
21. Eltzschig H.K., Eckle T. Ischemia and reperfusion-from mechanism to translation. Nat Med 2011, 17:1391-1401.
22. Yellon D.M., Hausenloy D.J. Myocardial reperfusion injury. NEngl J Med 2007, 357:1121-1135.
23. Rodrigo R., Fernandez-Gajardo R., Gutierrez R., et al. Oxidative stress and pathophysiology of ischemic stroke: novel therapeutic opportunities. CNS Neurol Disord Drug Targets 2013, 12:698-714.
24. Vollmar B., Menger M.D. Intestinal ischemia/reperfusion: microcirculatory pathology and functional consequences. Langenbecks Arch Surg 2011, 396:13-29.
25. Kaul D.K., Hebbel R.P. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. JClin Invest 2000, 106:411-420.
26. Belcher J.D., Bryant C.J., Nguyen J., et al. Transgenic sickle mice have vascular inflammation. Blood 2003, 101:3953-3959.
27. Osarogiagbon U.R., Choong S., Belcher J.D., et al. Reperfusion injury pathophysiology in sickle transgenic mice. Blood 2000, 96:314-320.
28. Dasgupta T., Hebbel R.P., Kaul D.K. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic Biol Med 2006, 41:1771-1780.
29. Aslan M., Freeman B.A. Redox-dependent impairment of vascular function in sickle cell disease. Free Radic Biol Med 2007, 43:1469-1483.
30. Ou J., Ou Z., Jones D.W., et al. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003, 107:2337-2341.
31. Polanowska-Grabowska R., Wallace K., Field J.J., et al. P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. Arterioscler Thromb Vasc Biol 2010, 30:2392-2399.
32. Solovey A.A., Solovey A.N., Harkness J., et al. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 2001, 97:1937-1941.
33. Solovey A., Kollander R., Shet A., et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 2004, 104:840-846.
34. Vinchi F., De Franceschi L., Ghigo A., et al. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation 2013, 127:1317-1329.
35. Kaul D.K., Zhang X., Dasgupta T., et al. Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress. Am J Physiol Heart Circ Physiol 2008, 295:H39-H47.
36. Nath K.A., Shah V., Haggard J.J., et al. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1949-R1955.
37. Kaul D.K., Liu X.D., Fabry M.E., et al. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am J Physiol Heart Circ Physiol 2000, 278:H1799-H1806.
38. Kalambur V.S., Mahaseth H., Bischof J.C., et al. Microvascular blood flow and stasis in transgenic sickle mice: utility of a dorsal skin fold chamber for intravital microscopy. Am J Hematol 2004, 77:117-125.
39. Belcher J.D., Mahaseth H., Welch T.E., et al. Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. Am J Physiol Heart Circ Physiol 2005, 288:H2715-H2725.
40. Aufradet E., DeSouza G., Bourgeaux V., et al. Hypoxia/reoxygenation stress increases markers of vaso-occlusive crisis in sickle SAD mice. Clin Hemorheol Microcirc 2013, 54:297-312.
41. Cain D.M., Vang D., Simone D.A., et al. Mouse models for studying pain in sickle disease: effects of strain, age, and acuteness. Br J Haematol 2012, 156:535-544.
42. Vincent L., Vang D., Nguyen J., et al. Mast cell activation contributes to sickle cell pathobiology and pain. Blood 2013, 122(11):1853-1862.
43. Hebbel R.P., Osarogiagbon R., Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 2004, 11:129-151.
44. Hebbel R.P., Vercellotti G., Nath K.A. Asystems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemo-prophylaxis. Cardiovasc Hematol Disord Drug Targets 2009, 9:271-292.
45. Akinola N.O., Stevens S.M., Franklin I.M., et al. Subclinical ischaemic episodes during the steady state of sickle cell anaemia. JClin Pathol 1992, 45:902-906.
46. Singhal A., Doherty J.F., Raynes J.G., et al. Is there an acute-phase response in steady-state sickle cell disease?. Lancet 1993, 341:651-653.
47. Stuart J., Stone P.C., Akinola N.O., et al. Monitoring the acute phase response to vaso-occlusive crisis in sickle cell disease. JClin Pathol 1994, 47:166-169.
48. Embury S.H. The not-so-simple process of sickle cell vasoocclusion. Microcirculation 2004, 11:101-113.
49. Reiter C.D., Wang X., Tanus-Santos J.E., et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002, 8:1383-1389.
50. Figueiredo R.T., Fernandez P.L., Mourao-Sa D.S., et al. Characterization of heme as activator of Toll-like receptor 4. JBiol Chem 2007, 282:20221-20229.
51. Ogunshola O.O., Bogdanova A.Y. Epo and non-hematopoietic cells: what do we know?. Methods Mol Biol 2013, 982:13-41.
52. Selvaraj S.K., Giri R.K., Perelman N., et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003, 102:1515-1524.
53. Ferwerda B., McCall M.B., Verheijen K., et al. Functional consequences of toll-like receptor 4 polymorphisms. Mol Med 2008, 14:346-352.
54. Schnabel R.B., Baumert J., Barbalic M., et al. Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood 2010, 115:5289-5299.
55. Kangelaris K.N., Sapru A., Calfee C.S., et al. The association between a Darc gene polymorphism and clinical outcomes in African American patients with acute lung injury. Chest 2012, 141:1160-1169.
56. Celermajer D.S., Adams M.R., Clarkson P., et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. NEngl J Med 1996, 334:150-154.
57. Faller S., Hoetzel A. Carbon monoxide in acute lung injury. Curr Pharm Biotechnol 2012, 13:777-786.
58. Belhassen L., Pelle G., Sediame S., et al. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 2001, 97:1584-1589.
59. Gladwin M.T., Schechter A.N., Ognibene F.P., et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 2003, 107:271-278.
60. Hebbel R.P. Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol 2011, 86:123-154.
61. Vichinsky E.P., Neumayr L.D., Earles A.N., et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. NEngl J Med 2000, 342:1855-1865.
62. Boyd J.H., Macklin E.A., Strunk R.C., et al. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood 2006, 108:2923-2927.
63. Cohen R.T., DeBaun M.R., Blinder M.A., et al. Smoking is associated with an increased risk of acute chest syndrome and pain among adults with sickle cell disease. Blood 2010, 115:3852-3854.
64. Vercellotti G.M., Yin H.Q., Gustafson K.S., et al. Platelet-activating factor primes neutrophil responses to agonists: role in promoting neutrophil-mediated endothelial damage. Blood 1988, 71:1100-1107.
65. Moore E.E., Moore F.A., Franciose R.J., et al. The postischemic gut serves as a priming bed for circulating neutrophils that provoke multiple organ failure. JTrauma 1994, 37:881-887.
66. Ballas S.K., Files B., Luchtman-Jones L., et al. Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome. Hemoglobin 2006, 30:165-170.
67. Akuete K., Oh S.S., Thyne S., et al. Ethnic variability in persistent asthma after in utero tobacco exposure. Pediatrics 2011, 128:e623-e630.
68. An P., Barron-Casella E.A., Strunk R.C., et al. Elevation of IgE in children with sickle cell disease is associated with doctor diagnosis of asthma and increased morbidity. JAllergy Clin Immunol 2011, 127:1440-1446.
69. Bax H.J., Keeble A.H., Gould H.J. Cytokinergic IgE action in mast cell activation. Front Immunol 2012, 3:229.
70. Sandig H., Bulfone-Paus S. TLR signaling in mast cells: common and unique features. Front Immunol 2012, 3:185.
71. Hu R., Xu H., Jiang H., et al. The role of TLR4 in the pathogenesis of indirect acute lung injury. Front Biosci (Landmark Ed) 2013, 18:1244-1255.
72. Holtzclaw J.D., Jack D., Aguayo S.M., et al. Enhanced pulmonary and systemic response to endotoxin in transgenic sickle mice. Am J Respir Crit Care Med 2004, 169:687-695.
73. Solovey A., Gui L., Ramakrishnan S., et al. Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. Blood 1999, 93:3824-3830.
74. Wei P., Milbauer L.C., Enenstein J., et al. Differential endothelial cell gene expression by African Americans versus Caucasian Americans: a possible contribution to health disparity in vascular disease and cancer. BMC Med 2011, 9:2.
75. Ballas S.K., Gupta K., Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood 2012, 120:3647-3656.
76. Wallace K.L., Linden J. Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood 2010, 116:5010-5020.
77. Ioannou A., Dalle Lucca J., Tsokos G.C. Immunopathogenesis of ischemia/reperfusion-associated tissue damage. Clin Immunol 2011, 141:3-14.
78. Belcher J.D., Young M., Chen C., et al. MP4CO, a pegylated hemoglobin saturated with carbon monoxide is a modulator of HO-1, inflammation and vaso-occlusion in transgenic sickle mice. Blood 2013, 122(15):2757-2764.
79. Kaul D.K., Liu X.D., Choong S., et al. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol 2004, 287:H293-H301.
80. Mahaseth H., Vercellotti G.M., Welch T.E., et al. Polynitroxyl albumin inhibits inflammation and vasoocclusion in transgenic sickle mice. JLab Clin Med 2005, 145:204-211.
81. Kaul D.K., Liu X.D., Zhang X., et al. Inhibition of sickle red cell adhesion and vasoocclusion in the microcirculation by antioxidants. Am J Physiol Heart Circ Physiol 2006, 291:H167-H175.
82. Kaul D.K., Kollander R., Mahaseth H., et al. Robust vascular protective effect of hydroxamic acid derivatives in a sickle mouse model of inflammation. Microcirculation 2006, 13:489-497.
83. Hebbel R.P., Vercellotti G.M., Pace B.S., et al. The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood 2010, 115:2483-2490.
84. Kollander R., Solovey A., Milbauer L.C., et al. Nuclear factor-kappa B (NFkappaB) component p50 in blood mononuclear cells regulates endothelial tissue factor expression in sickle transgenic mice: implications for the coagulopathy of sickle cell disease. Transl Res 2010, 155:170-177.
85. Belcher J.D., Vineyard J.V., Bruzzone C.M., et al. Heme oxygenase-1 gene delivery by Sleeping Beauty inhibits vascular stasis in a murine model of sickle cell disease. JMol Med (Berl) 2010, 88:665-675.
86. Belcher J., Nguyen J., Chen C., et al. Plasma hemoglobin and heme trigger Weibel Palade body exocytosis and vaso-occlusion in transgenic sickle mice. Blood 2011, 118:896. [abstract].
87. Smith C.M., Hebbel R.P., Tukey D.P., et al. Pluronic F-68 reduces the endothelial adherence and improves the rheology of liganded sickle erythrocytes. Blood 1987, 69:1631-1636.
88. Solovey A., Kollander R., Milbauer L.C., et al. Endothelial nitric oxide synthase and nitric oxide regulate endothelial tissue factor expression invivo in the sickle transgenic mouse. Am J Hematol 2010, 85:41-45.
89. Solovey A., Somani A., Chen C., et al. Interference with TNF-alpha using long-term Etanercept in S+SAntilles sickle transgenic mice ameliorates abnormal endothelial activation, vasoocclusion, and pulmonary hypertension including its pulmonary aterial wall remodeling. Blood 2013, 122:728. [Abstract].
90. Pritchard K.A., Ou J., Ou Z., et al. Hypoxia-induced acute lung injury in murine models of sickle cell disease. Am J Physiol Lung Cell Mol Physiol 2004, 286:L705-L714.